NCT04985357 2024-11-25Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsTravera IncWithdrawn
NCT06090318 2023-10-19Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A LossRain Oncology IncPhase 1/2 Withdrawn